Gynaecological Cancers Risk
The International Agency for Research on Cancer suggests that the burden of women’s cancers including breast, ovarian, and womb will rise by 50% over the next 20 years. It is essential for us to improve early diagnosis and prevention of these cancers in our health systems. The last decade has seen s...
Đã lưu trong:
| Định dạng: | Online |
|---|---|
| Ngôn ngữ: | Tiếng Anh |
| Được phát hành: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Những chủ đề: | |
| Truy cập trực tuyến: | ONIX_20220224_9783036529837_92 |
| Các nhãn: |
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
| _version_ | 1869518324435517440 |
|---|---|
| collection | Directory of Open Access Books |
| description | The International Agency for Research on Cancer suggests that the burden of women’s cancers including breast, ovarian, and womb will rise by 50% over the next 20 years. It is essential for us to improve early diagnosis and prevention of these cancers in our health systems. The last decade has seen significant strides in our ability to understand and predict a woman’s risk of these cancers and offer personalized medicine approaches for risk management. There have been improvements in identifying individuals at increased risk, as well as implementing and evaluating strategies for screening and prevention. In this special collection, we bring together 16 articles from leading scientists and researchers. These capture some of the important advances observed in estimating cancer risk, providing genetic testing, offering risk management to those at increased risk, as well as screening and prevention of breast, ovarian, and womb cancers in women. This makes an important contribution to the rapidly advancing knowledge base across the area of personalized medicine and precision prevention of ovarian, endometrial, and breast cancers. |
| format | Online |
| id | doab-20.500.12854ir-78794 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-787942024-03-31T13:08:59Z Gynaecological Cancers Risk Manchanda, Ranjit breast cancer galectins galectin-7 galectin-8 prognostic markers tumor infiltrating macrophages screening mammography incidence-based mortality population genetic testing ovarian cancer risk risk stratification BRCA1 BRCA2 RAD51C RAD51D BRIP1 SNP risk modelling BRCA population testing cost-effectiveness ovarian cancer cancer prevention CA125 HE4 UKCTOCS MMT postmenopausal women rare germline variants susceptibility genes genomics questionnaires attitudes symptoms early detection risk assessment diagnostic prediction model triage tool ovarian cancer symptoms family history risk genes prevention dyskerin DKC1 endometrial cancer telomerase proliferation telomeres obesity metabolomics liquid biopsy mass spectrometry plasma biomarkers artificial intelligence ultrasound TVS trial randomised controlled trial genomic sequencing tumor mutational signatures hereditary cancer genes mismatch repair familial cancer menopausal hormone therapy breast cancer risk BMI early BMI age of pregnancy mammographic density body mass index weight loss breast cancer prevention premenopausal genetic testing germline somatic n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine The International Agency for Research on Cancer suggests that the burden of women’s cancers including breast, ovarian, and womb will rise by 50% over the next 20 years. It is essential for us to improve early diagnosis and prevention of these cancers in our health systems. The last decade has seen significant strides in our ability to understand and predict a woman’s risk of these cancers and offer personalized medicine approaches for risk management. There have been improvements in identifying individuals at increased risk, as well as implementing and evaluating strategies for screening and prevention. In this special collection, we bring together 16 articles from leading scientists and researchers. These capture some of the important advances observed in estimating cancer risk, providing genetic testing, offering risk management to those at increased risk, as well as screening and prevention of breast, ovarian, and womb cancers in women. This makes an important contribution to the rapidly advancing knowledge base across the area of personalized medicine and precision prevention of ovarian, endometrial, and breast cancers. 2022-02-24T10:36:43Z 2022-02-24T10:36:43Z 2022 book ONIX_20220224_9783036529837_92 9783036529837 9783036529820 https://directory.doabooks.org/handle/20.500.12854/78794 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4889 https://mdpi.com/books/pdfview/book/4889 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2983-7 10.3390/books978-3-0365-2983-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036529837 9783036529820 338 Basel open access |
| spellingShingle | breast cancer galectins galectin-7 galectin-8 prognostic markers tumor infiltrating macrophages screening mammography incidence-based mortality population genetic testing ovarian cancer risk risk stratification BRCA1 BRCA2 RAD51C RAD51D BRIP1 SNP risk modelling BRCA population testing cost-effectiveness ovarian cancer cancer prevention CA125 HE4 UKCTOCS MMT postmenopausal women rare germline variants susceptibility genes genomics questionnaires attitudes symptoms early detection risk assessment diagnostic prediction model triage tool ovarian cancer symptoms family history risk genes prevention dyskerin DKC1 endometrial cancer telomerase proliferation telomeres obesity metabolomics liquid biopsy mass spectrometry plasma biomarkers artificial intelligence ultrasound TVS trial randomised controlled trial genomic sequencing tumor mutational signatures hereditary cancer genes mismatch repair familial cancer menopausal hormone therapy breast cancer risk BMI early BMI age of pregnancy mammographic density body mass index weight loss breast cancer prevention premenopausal genetic testing germline somatic n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine Gynaecological Cancers Risk |
| title | Gynaecological Cancers Risk |
| title_full | Gynaecological Cancers Risk |
| title_fullStr | Gynaecological Cancers Risk |
| title_full_unstemmed | Gynaecological Cancers Risk |
| title_short | Gynaecological Cancers Risk |
| title_sort | gynaecological cancers risk |
| topic | breast cancer galectins galectin-7 galectin-8 prognostic markers tumor infiltrating macrophages screening mammography incidence-based mortality population genetic testing ovarian cancer risk risk stratification BRCA1 BRCA2 RAD51C RAD51D BRIP1 SNP risk modelling BRCA population testing cost-effectiveness ovarian cancer cancer prevention CA125 HE4 UKCTOCS MMT postmenopausal women rare germline variants susceptibility genes genomics questionnaires attitudes symptoms early detection risk assessment diagnostic prediction model triage tool ovarian cancer symptoms family history risk genes prevention dyskerin DKC1 endometrial cancer telomerase proliferation telomeres obesity metabolomics liquid biopsy mass spectrometry plasma biomarkers artificial intelligence ultrasound TVS trial randomised controlled trial genomic sequencing tumor mutational signatures hereditary cancer genes mismatch repair familial cancer menopausal hormone therapy breast cancer risk BMI early BMI age of pregnancy mammographic density body mass index weight loss breast cancer prevention premenopausal genetic testing germline somatic n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine |
| topic_facet | breast cancer galectins galectin-7 galectin-8 prognostic markers tumor infiltrating macrophages screening mammography incidence-based mortality population genetic testing ovarian cancer risk risk stratification BRCA1 BRCA2 RAD51C RAD51D BRIP1 SNP risk modelling BRCA population testing cost-effectiveness ovarian cancer cancer prevention CA125 HE4 UKCTOCS MMT postmenopausal women rare germline variants susceptibility genes genomics questionnaires attitudes symptoms early detection risk assessment diagnostic prediction model triage tool ovarian cancer symptoms family history risk genes prevention dyskerin DKC1 endometrial cancer telomerase proliferation telomeres obesity metabolomics liquid biopsy mass spectrometry plasma biomarkers artificial intelligence ultrasound TVS trial randomised controlled trial genomic sequencing tumor mutational signatures hereditary cancer genes mismatch repair familial cancer menopausal hormone therapy breast cancer risk BMI early BMI age of pregnancy mammographic density body mass index weight loss breast cancer prevention premenopausal genetic testing germline somatic n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine |
| url | ONIX_20220224_9783036529837_92 |